Abstract
BackgroundAcinetobacter baumannii is recognized as a major threat that causes healthcare-associated infections and causes a huge challenge to the health system worldwide. This research study was designed to detect the types and profiles of antibiotics tested against A. baumannii clinical strains in Turkey to evaluate their effectiveness and reevaluate their usage.Main body of the abstractThe study depended on data search strategy using the online electronic database. We carried out a detailed analysis to all original research articles from 2011 to 2022 all conducted in Turkey. The study involved 91 articles and revealed about 40 antibiotics tested from 2006 to 2021 against A. baumannii with a different frequency. The more frequency antibiotics tested by health institutions in Turkey during this period included 15 antibiotics which are (Amikacin, Gentamicin, Imipenem, Meropenem, Cefoperazone–sulbactam, Ceftazidime, Cefepime, Ampicillin/sulbactam, Piperacillin, Piperacillin/tazobactam, Ciprofloxacin, Levofloxacin, Trimethoprim–Sulfamethoxazole, Colistin and Tigecycline). The frequency of resistance rate with percentage of (80–100%) shown by A. baumannii against these antibiotics was as follows (40.96%, 50.64%, 77.77%, 78.31%, 46.15%, 94.11%, 88.23%, 80.85%, 95.46%, 91.93%, 93.42%, 82.85%, 53.57%, 2.66%, 3.70%), respectively. From 2016 to 2021, an increase in resistance rates by A. baumannii against Colistin and Tigecycline was indicated noticeably. The 0% resistance rates during this period against Colistin were reported in a percentage of 16.6%, while the appearance of highly noticeable resistance (from 80 to 100 = 3.70%) against Tigecycline and the continuous elevation of resistance rates against this drug was worrisome.Short conclusionStability in high resistance rates against some antibiotics for the last 10 years and the increase in resistance rates against effective antibiotics by A. baumannii should undergo for more studies and re-evaluation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have